At the beginning of 2025, Helen Swan was told she had months to live. A Scottish grandmother-to-be has started ...

Smoking status added to the National Cancer Database for patients diagnosed with cancer in 2023 revealed variations in ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

What's been going on in the life sciences world this week? Check out Week in Brief for an overview of the biggest news.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment prolongs survival.

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Since 1971, the US has led the world in funding cancer research and developing new treatments that have driven down death ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...